Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a Clinical Study Agreement with the Contract Research Organization (CRO) Centre for Human Drug Research (CHDR) to conduct an early phase human clinical trial with DMT. CHDR is a Leiden, Netherlands-based contract research...
2020-12-01 8:30 AM EST
Entheon Biomedical to Begin Trading on the Frankfurt Exchange
Vancouver, British Columbia--(Newsfile Corp. - November 26, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that its shares have commenced trading on the Frankfurt Stock Exchange under the symbol "1XU1". The Frankfurt Stock Exchange is the world's tenth largest organized exchange-trading market in terms of turnover and dealings in securities....
2020-11-26 8:30 AM EST
Entheon Biomedical Corp. Commences Trading on the Canadian Securities Exchange
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (formerly, MPV Exploration Inc.) ("Entheon" or the "Company") is pleased to announce that, further to its news release dated November 5, 2020, the Company has commenced trading on the Canadian Securities Exchange ("CSE") under the symbol "ENBI". Timothy Ko, CEO of Entheon, stated: "We are thrilled by the opportunity that listing on the CSE presents. Addiction is a massive societal issue...
2020-11-12 8:30 AM EST
Entheon Biomedical Corp. (formerly MPV Exploration Inc.) Announces Completion of Amalgamation and Final Approval from the Canadian Securities Exchange
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2020) - Entheon Biomedical Corp. (CSE: MPV) (formerly, MPV Exploration Inc.) ("Entheon" or the "Company") is pleased to announce that further to its news releases dated July 2, 2020, September 10, 2020 and October 28, 2020, the Company has completed the previously announced business combination with Entheon Holdings Corp. (formerly, Entheon Biomedical Corp.) and has received final approval to list the Resulting Issuer Shares (as...
2020-11-05 7:59 PM EST
Entheon Biomedical Announces Private Placement to Begin Pre-clinical Trials with Psychedelic Compounds DMT & 5 MEO DMT
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2020) - Entheon Biomedical Corp. ("Entheon" or the "Company") announces that it intends to complete a private placement of up to 10,000,000 units (the "Units") at a price of $0.40 CDN per Unit for total gross proceeds of up to Cdn$4,000,000. Each Unit will consist of one common share and one-half of one warrant. Each whole warrant (a "Warrant") will entitle the holder to purchase one common share at a price of $0.60 for two years from the...
2020-05-07 6:30 AM EDT